As expected, our results revealed substantially increases in levels of ALT, GGT, and TGF-β in patients with steatosis compared to those without steatosis, and all of such makers have been associated with NASH prediction [43]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.